AIRJ Expands Strategic Partnerships and Advances Productization of AirJoule™ Systems Ahead of Commercial Deployments in 2026 RONAN, Mont., Nov. 13, 2025 (GLOBE NEWSWIRE) — AirJoule Technologies Corporation (NASDAQ: AIRJ) (“AirJoule Technologies” or “AIRJ”), a leading technology platform that unleashes the power of water from air, today announced its third quarter 2025 results and provided a business update highlighting progress toward near-term commercialization. “AirJoule Technologies is addressing emerging opportunities driven by powerful macro trends that are fundamentally reshaping global water and energy markets,” said Matt Jore, Chief Executive Officer of AirJoule Technologies. “Water scarcity is intensifying across key industrial and population centers. Data center expansion is driving unprecedented demand for sustainable...

Third Quarter 2025 Revenues Increased 41% to $7.4 Million, Driving Net Income of $0.8 Million CORSICANA, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) — Birchtech Corp. (TSX: BCHT) (OTCQB: BCHT) (“Birchtech” or the “Company”), a leader in specialty activated carbon technologies for sustainable air and water treatment, today reported financial results for the third quarter ended September 30, 2025. Key Third Quarter 2025 & Subsequent Operational HighlightsPending final judgment following the $57 million patent infringement verdict, from which the Company’s counsel requested $160 million inclusive of enhancements, interest and legal fees. Four key air business licensing agreements secured, with the potential to transition into long-term product supply agreements:A non-exclusive licensing agreement with a large regional coal-fired...

Business highlights include:Three new top-rated children’s hospitals adopt QUELIMMUNE therapy for ultra-rare pediatric Acute Kidney Injury (AKI) Commercial use of QUELIMMUNE therapy demonstrates positive survival results as reported from the QUELIMMUNE SAVE Surveillance Registry New clinical sites added to expand adult NEUTRALIZE-AKI pivotal trial enrollment Strengthened the balance sheet, raising $12.4 million to fund future operations Webcast call today at 4:30 p.m. Eastern TimeDENVER, Nov. 13, 2025 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today financial results for the three months ended September 30, 2025, and provided business updates...

Entered into an exclusive license agreement with Dynavax for the Company’s COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment of approximately 5,400 participants in COVID-19 Phase 2b trial with topline data expected in late 2026; Topline data from 400-person sentinel cohort anticipated in the first quarter of 2026 Reported additional supportive data from Phase 1 clinical trial evaluating Company’s second-generation oral norovirus vaccine constructs, demonstrating potential for improved protection against infection; Company continues to explore partnership opportunities Cash, cash equivalents and investments of $28.8 million as of September 30, 2025; Current runway extended into second quarter of 2027 Conference call today at 4:30 p.m. ET Live stockholder fireside...

SALT LAKE CITY, Nov. 13, 2025 (GLOBE NEWSWIRE) — Security National Financial Corporation (SNFC) (NASDAQ symbol “SNFCA”) announced financial results for the quarter ended September 30, 2025. For the three months ended September 30, 2025, SNFC’s after tax earnings decreased 34% from $11,831,000 in 2024 to $7,815,000 in 2025. For the nine months ended September 30, 2025, after tax earnings decreased 30% to $18,866,000 from $26,578,000 in 2024. Scott M. Quist, President of the Company, said: “While the third quarter was definitely weak from my point of view, being $4MM below Q3 2024 or roughly 34%, there are some definite bright spots which partially illuminate much of the hard work that has gone on. For example, on a Return On Equity basis, as of September 30th we achieved a 7.9% ROE for the nine months, which if annualized...

Q3 2025 net product revenue increased 223% year-over-year to $438 thousand Gross profit/(loss) decreased from $24 thousand to $(100) thousandWASHINGTON, Nov. 13, 2025 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, reported today its financial results for the third fiscal quarter of the 2025 year, ended September 30, 2025. Financial Highlights for the Quarter Ended September 30, 2025:ARAKODA® pharmacy deliveries increased by 14% from 1,319 boxes (Q3 2024) to 1,505 boxes (Q3 2025). The Company posted a gross loss of approximately $100 thousand in the third quarter of 2025, compared to an approximate gross profit of $24 thousand in the third quarter of 2024, due to a one-time inventory write-off associated...

JEFFERSONVILLE, N.Y., Nov. 13, 2025 (GLOBE NEWSWIRE) — Jeffersonville Bancorp, Inc. (OTCQB – JFBC) announced today third quarter net income of $3,293,000 or $0.78 per share compared to $3,092,000 or $0.73 per share for the same quarter in 2024. The increase in quarterly net income compared to 2024 of $201,000 was primarily attributable to a reduction in interest expense of $554,000 and an increase of $500,000 in loan interest and fees, partially offset by a reduction in other interest and dividend income of $277,000, a reduction in securities interest of $203,000, a gain on sale of foreclosed real estate of $191,000 in 2024, an increase in non-interest expense of $115,000, and an increase in income tax expense of $40,000. Year to date net income as of September 30, 2025 was $9,301,000 or $2.20 per share compared to $8,676,000...

Excellent commercial momentum, fuelled by Rolling Stock and North AmericaGroup book-to-bill ratio1 of 1.2 Rolling Stock book-to-bill ratio1 of 1.4All product lines contributing to strong sales growthGroup sales at €9,059 million, up 3.2%, of which 7.9% on an organic1 basis Strong sales performance in Europe (up 8.5%) supported by both Rolling Stock and SignallingSteady margin progressionAdjusted EBIT1 up 13% to €580 million compared to H1 2024/25 Adjusted EBIT margin1 of 6.4%, up 50bps compared to H1 2024/25Free-Cash-Flow seasonality as expectedContinuous progression in Funds From Operations1 (FFO) at €411 million Free-Cash-Flow1 (FCF) of €(740) million, reflecting expected working capital seasonalityNet profit (Group share) of €220 million, compared to €53 million for the first semester of fiscal year 2024/25 FY...

REGULATED INFORMATIONBrussels, 13 November 2025, 5:55 PMRESULTS ON Q3 2025HIGHLIGHTS  NEXTENSA ACHIEVES SOLID RESULTS IN Q3 In the third quarter of 2025 Nextensa maintained its strong momentum and achieved a clear increase in profitability. Net profit increased significantly, driven by a higher contribution of development activities, lower financing costs and a further strengthening of the balance sheet. Three significant transactions were completed in Q3 2025:Sale of Retail Estates. On August 28,2025, Nextensa has sold its entire 8.99% stake in the Belgian REIT Retail Estates, generating proceeds of €89.6 M. Sale of Monteco in Belgium on September 17, 2025: 100% of the shares of Monteco BV were sold jointly with ION for a valuation of €28 M. Sale of retail property in Ingeldorf, Luxembourg, on September 29, 2025, to the State of...

        PRESS RELEASE                Paris, 13th November 2025 Interim results at the end of September 2025 Revenue growth of 2.6% and Group EBITDA up 6.5% despite reduction in public funding; resilient operating performance Activity growth and cost control compensate constrained fundingUnaudited group revenue for the quarter ending 30 September 2025 increased by 2.6% to 1.21bn€ supported by activity volume growth, price indexation in Sweden and favourable foreign exchange movements. Revenue growth of 1.9% on a like-for-like basis. Acute hospitals admission volume growth in France and Sweden despite 1 less business day this quarter compared to the same period last year, reflecting sustained patient need for healthcare and the capacity of the group’s facilities to provide more quality care services in a competitive landscape. Unaudited...